Please login to the form below

Not currently logged in
Email:
Password:

Heart drug

This page shows the latest Heart drug news and features for those working in and with pharma, biotech and healthcare.

AZ prepares to file COPD triple, taking on rival GSK

AZ prepares to file COPD triple, taking on rival GSK

The data reveals that the drug was better than two-drug combinations in preventing COPD exacerbations, reducing attacks by 52% compared to AZ’s LAMA/LABA combination Bevespi (glycopyrronium/formoterol fumarate). ... As the two drug combinations are at

Latest news

  • Real-world data finds patients feel better on Entresto, says Novartis Real-world data finds patients feel better on Entresto, says Novartis

    The drug was approved to treat chronic heart failure patients with reduced ejection fraction (HFrEF) or systolic dysfunction in 2015 and - after a sluggish start - finally seems to be developing sales ... There wasn’t much to report on in terms of new

  • Amgen gets prevention claim for cholesterol drug Repatha Amgen gets prevention claim for cholesterol drug Repatha

    Amgen gets prevention claim for cholesterol drug Repatha. FDA approves new labelling on heart attack and stroke risk reduction. ... The US FDA has approved new labelling saying that Amgen’s cholesterol drug Repatha can reduce the risk of heart attacks

  • Vas Narasimhan takes top Novartis job on Jimenez departure Vas Narasimhan takes top Novartis job on Jimenez departure

    Harvard -trained physician Narasimhan has been with Novartis since 2005 and has held a number of roles at the company across commercial, drug development and strategy but is "deeply anchored in ... showed an uptick in performance but remains under

  • Alcon's return to growth gives Novartis 'options', says CEO Alcon's return to growth gives Novartis 'options', says CEO

    Immunotherapy Cosentyx (secukinumab) for psoriasis, ankylosing spondylitis and psoriatic arthritis rocketed 90% to reach $490m in the quarter, while slow-burner Entresto (sacubitril and valsartan) for heart failure contributed $110m and ... A string of

  • New drugs can't keep Novartis sales on the up New drugs can't keep Novartis sales on the up

    The continued glacial growth of Novartis' heart failure hope Entresto weighed on its first-quarter results as sales declined on generic competition. ... year. A decision to drop development of acute heart failure drug serelaxin (RLX030) also pegged back

More from news
Approximately 1 fully matching, plus 179 partially matching documents found.

Latest Intelligence

  • Transforming Access to Medicines Through Patient-Centric Solutions Transforming Access to Medicines Through Patient-Centric Solutions

    to medicines and the importance of putting patients at the heart of drug development and access. ... Patients at the heart of drug development and access. If you believe the news every day, patients are becoming more and more involved in drug development

  • Transforming Access to Medicines Through Patient-Centric Solutions Transforming Access to Medicines Through Patient-Centric Solutions

    to medicines and the importance of putting patients at the heart of drug development and access. ... Patients at the heart of drug development and access. If you believe the news every day, patients are becoming more and more involved in drug development

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    Ivabradine is thought to be the first drug to work by decreasing the heart rate as a consequence of its action on the If channel that controls the intrinsic pacemaker in ... In the 6, 500-patient SHIFT trial, for example, the drug showed a significant

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    She gives the example of a drug to prevent a second heart attack that has a positive NICE recommendation, can save people's lives and reduce further hospital costs. “ ... After a heart attack people tend to leave the hospital thinking the event is over.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics